Earnings Call · Q3 FY2023·2023-11-07

Q3 23EPS 0.00%·Rev n/aQ2 23EPS -10.00%·Rev n/aQ1 23EPS -6.25%·Rev n/aQ4 22EPS +6.67%·Rev n/a⚠ consensus missing

Evolus, Inc. EOLS

Ned Mitchell — Investor Relations

David Moatazedi — President and Chief Executive Officer

Rui Avelar — Chief Medical Officer and Head of R&D

Sandra Beaver — Chief Financial Officer

+8.2%1d on move date+8.1% vs SPY3d−1.0%5d+4.6%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more EOLS calls or request research access.

More EOLS calls Browse calls Request research access